In this session, Dr. De Santi will provide an update on Amyloid PET Imaging and its tracers, in particular florbetaben F18 injection (NeuraceqTM), including key attributes, and more.
Read MoreSOFIE Inc. (SOFIE), a Theranostics company headquartered in Los Angeles, CA, expands its footprint in Totowa, NJ. The acquired space is being used for the construction of a new Radiopharmaceutical Contract Manufacturing Center of Excellence (COE).
Read MoreSOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics (“theranostics”) that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells.
Read MoreLos Angeles-based SOFIE Inc. (SOFIE), a molecular imaging and theranostic company, announces the acquisition of a Cyclotope Radiopharmacy from Houston Cyclotron Partners.
Read MoreIn this session, Darcy Phillips (BS, CNMT) will focus on how Nuclear Medicine and PET/CT programs can implement strategies to maximize service to physicians and their patients, while ensuring the effectiveness of clinical and administrative staff, and more.
Read MoreIn this session, Dr. Bridwell will review the major aims and aspects of the Neck Imaging Reporting & Data System (NI-RADS) and more.
Read More